CHAPTER 137 HUMAN LEUKOCYTE AND PLATELET ANTIGENS Flashcards
(80 cards)
Two major classes of HLA and their examples
class I (A, B, and C loci)
class II (DR, DQ, and DP loci)
primarily expressed on B cells and other antigen-presenting cells such as dendritic cells, endothelial cells, and monocytes
class II (DR, DQ, and DP loci)
human leukocyte antigens play key roles in: (3)
1) HSC transplantation acceptance/ rejection
2) allosensitization to non-leukoreduced blood transfusions leading to platelet transfusion refractoriness,
3) lesser, in solid- organ transplantation
HLA are highly polymorphic glycoproteins encoded by a region of genes known as the major histocompatibility complex (MHC) located on
chromosome 6p21
T/F: After ABO antigens, HLA antigens are the major barrier to transplantation.
True
Are ubiquitous and present on most nucleated somatic cells
Class I antigens
Exhibit more restricted distribution, with varying levels of expression on B cells, dendritic cells, monocytes, macrophages, and endothelial cells.
Class II antigens
T/F: class II antigens can be induced on many cell types through activation.
True
nonclassical class Ib antigens
- much less polymorphic
- function less understood
HLA-E, HLA-F, and HLA-G
Antibodies recognizing platelet-specific alloantigens have been discovered in three clinical situations:
- mothers who give birth to infants with FNAIT;
- patients who develop dramatic thrombocytopenia after blood transfusion (PTP);
- and patients who have received multiple transfusions.
principal cause of immunologic platelet transfusion refractoriness
class I HLA antigens
T/F: occasionally patients receiving multiple platelet transfusions will develop antibodies to platelet specific alloantigens.
True
If platelet transfusion refractoriness does develop because of platelet- specific antibodies, compatible platelet products may be identified by: (2)
1) using either platelet crossmatching or
2) by accessing family member or other HPA-typed donors who are compatible with the patient’s antibodies
T/F: Antibodies against some HPA-allelic determinants can inhibit platelet function.
True
_____can inhibit clot retraction and platelet aggregation, presumably because they block the binding of GPIIb/IIIa (α β ) (CD41/CD61) to fibrinogen. –> identify the type of platelet function disease
- Anti–HPA-1 alloantibodies,
- GLANZMANN
______, lack platelet GPIb-V-IX (CD 42a-c)
Bernard-Soulier syndrome
_______ can completely inhibit aggregation of HPA-4 platelets that are homozygous for the allele recognized by the alloantibodies because the epitope is in close proximity to the RGD (arginine-glycine-aspartic acid peptide sequence)
Anti–HPA-4 alloantibodies
T/F: other anti–HPA-alloantibodies, such as those specific for HPA-3, may not significantly interfere with platelet function but nonetheless can cause Fc-mediated platelet destruction and immune thrombocytopenia
TRUE
result from transfusion of antibodies to recipient HPA
passive alloimmune thrombocytopenia
Transfusion of blood components containing antibodies to ____ and _____ have been reported to result in significant thrombocytopenia for 1 to 2 weeks.
HPA-1a and -5b
T/F: Many of the best-documented platelet-specific antibodies detected in such patients are directed against platelet antigens whose phenotypic frequencies are less than 30% in the blood-donor population.
Matching Type:
1. Anti–HPA-1 alloantibodies
2. Anti–HPA-3 alloantibodies
3. Anti–HPA-4 alloantibodies
4. Anti–HPA-1a and 5b alloantibodies
a. inhibit aggregation of HPA-4 platelets that are homozygous for the allele recognized by the alloantibodies because the epitope is in close proximity to the RGD
b. result in significant thrombocytopenia for 1 to 2 weeks
c. can inhibit clot retraction and platelet aggregation, presumably because they block the binding of GPIIb/IIIa (α β ) (CD41/CD61)
d. can cause Fc-mediated platelet destruction and immune thrombocytopenia
1, c
2, d
3, a
4, b
TESTING FOR PLATELET-SPECIFIC ANTIGENS AND ANTIBODIES
The earliest.
Involved mixing of patient serum with normal platelets and used platelet function-dependent end points such as α-granule release, aggregation, or agglutination.
Phase I
TESTING FOR PLATELET-SPECIFIC ANTIGENS AND ANTIBODIES
the only major phase I assay remaining in wide use today
serotonin release assay